Educational information, not medical advice.See how evidence is graded

Bremelanotide (Vyleesi)

Best studied for: Low sexual desire (women); Hypoactive sexual desire disorder (HSDD); Sexual dysfunction.

Home

What is Bremelanotide (Vyleesi)? Bremelanotide, sold as Vyleesi, is a synthetic peptide that works directly in the brain to boost sexual desire rather than acting on blood flow or hormones like most other treatments. It was FDA-approved in 2019 for premenopausal women with acquired, generalized HSDD — meaning low desire that developed over time and causes real distress. Unlike a daily pill, it is injected about 45 minutes before anticipated sexual activity on an as-needed basis. How does Bremelanotide (Vyleesi) work? Bremelanotide activates melanocortin receptors (particularly MC3R and MC4R) in the brain — areas linked to sexual arousal, motivation, and reward. Think of it as flipping on a 'desire signal' in the brain rather than relaxing blood vessels or adjusting hormone levels. This central mechanism is why it can increase desire even when hormonal levels are normal. What forms does Bremelanotide (Vyleesi) come in? Bremelanotide comes as a single-use, prefilled auto-injector pen delivering 1.75 mg subcutaneously (under the skin of the abdomen or thigh). It is not available as an oral supplement or over-the-counter product. Compounded versions of PT-141 are available through some specialty pharmacies but are not FDA-approved for this indication. Where it comes from: Originally investigated as a potential tanning agent (it does cause some skin darkening), bremelanotide was accidentally discovered to produce spontaneous erections in male researchers during early trials. This led to two decades of clinical development for sexual dysfunction in both men and women, culminating in FDA approval for HSDD in women in June 2019.

Helps

What does Bremelanotide (Vyleesi) help with? Low sexual desire (women) / HSDD: Bremelanotide is FDA-approved specifically for this. Clinical trials showed that women using it experienced meaningful improvements in satisfying sexual events and significantly less distress about their low desire compared to placebo. It works by activating brain reward and motivation circuits, not by changing hormone levels. Sexual arousal difficulties: Because bremelanotide acts centrally on the brain's desire-and-reward pathways, it can increase both the mental and physical aspects of arousal. Women in trials reported improvements in overall sexual function beyond just desire, including arousal and satisfaction. Distress from low libido: One of the two co-primary endpoints in pivotal trials was reduction in distress caused by low sexual desire. Women using bremelanotide reported feeling significantly less bothered or upset by their reduced libido, which is a clinically meaningful outcome on its own. Low sexual desire (men, off-label): Early human trials of PT-141 in men showed that it could increase sexual desire and arousal, including in men who did not fully respond to PDE5 inhibitors like Viagra. Though not FDA-approved for men, compounded PT-141 is used off-label in men's health settings. Erectile dysfunction (off-label, men): Early phase trials demonstrated that bremelanotide induced erections in men with psychogenic erectile dysfunction and some men with organic ED who were non-responders to sildenafil. The mechanism is central (brain-driven) rather than vascular, making it a different approach than standard ED medications. Psychogenic sexual dysfunction: Because bremelanotide targets brain-level desire pathways, it may be especially useful when sexual dysfunction has a significant psychological or motivational component rather than being purely physical or hormonal.

Bremelanotide (Vyleesi)

Quick Facts

  • What it is: A synthetic peptide injected under the skin that activates brain pathways involved in sexual desire — developed specifically for women with low libido.
  • Main uses: FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, and increasingly explored for sexual dysfunction in men.
  • Best for: Low sexual desire (women), Hypoactive sexual desire disorder (HSDD), Sexual dysfunction
  • Active ingredients: Bremelanotide (cyclic heptapeptide melanocortin receptor agonist)
  • Forms: subcutaneous auto-injector pen (1.75 mg)
  • Time to effect: 45 minutes to 1 hour after injection; sexual desire window lasts up to 12 hours.
  • Side effects: Nausea is the most common side effect, affecting about 40% of users; facial flushing, headache, and temporary blood pressure changes also occur.
  • Pregnancy & breastfeeding: Not assessed for this entry. Ask your doctor or midwife before use.

Educational information, not medical advice — ask your doctor or midwife.

What is Bremelanotide (Vyleesi)?

Bremelanotide, sold as Vyleesi, is a synthetic peptide that works directly in the brain to boost sexual desire rather than acting on blood flow or hormones like most other treatments. It was FDA-approved in 2019 for premenopausal women with acquired, generalized HSDD — meaning low desire that developed over time and causes real distress. Unlike a daily pill, it is injected about 45 minutes before anticipated sexual activity on an as-needed basis.

How does Bremelanotide (Vyleesi) work?

Bremelanotide activates melanocortin receptors (particularly MC3R and MC4R) in the brain — areas linked to sexual arousal, motivation, and reward. Think of it as flipping on a 'desire signal' in the brain rather than relaxing blood vessels or adjusting hormone levels. This central mechanism is why it can increase desire even when hormonal levels are normal.

What forms does Bremelanotide (Vyleesi) come in?

Bremelanotide comes as a single-use, prefilled auto-injector pen delivering 1.75 mg subcutaneously (under the skin of the abdomen or thigh). It is not available as an oral supplement or over-the-counter product. Compounded versions of PT-141 are available through some specialty pharmacies but are not FDA-approved for this indication.

Where it comes from:

Originally investigated as a potential tanning agent (it does cause some skin darkening), bremelanotide was accidentally discovered to produce spontaneous erections in male researchers during early trials. This led to two decades of clinical development for sexual dysfunction in both men and women, culminating in FDA approval for HSDD in women in June 2019.

Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.

Remedies related to Bremelanotide (Vyleesi)

The evidence behind this remedy, in one page

What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.

One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.